Stocks Moneycontrol

Despite not-so-impressive performance, MC Pro has a positive outlook on DCB Bank and sees a reasonable upside to the stock price supported by business growth and earnings in FY23. The bank has multiple levers to improve return ratios over the medium-long term and the management also intends to double the balance sheet in the next 3-4 years. Watch the video to know more.

Ideas for profit | GRSE: Should you buy the stock post 18% correction from recent high?

The share price of Garden Reach Shipbuilders and Engineers' (GRSE) has corrected recently led by overall weakness in the stock market. The stock has fallen from the high of Rs 324 per share in May 2022, to the current price of around Rs 260 apiece. Interestingly, with close to a 3 percent dividend yield, valuations are quite attractive at 9 times its FY24 estimated earnings. Should you invest for the long haul? Watch the video to find out

Ideas for profit | Strong growth despite commodity cost inflation; Should you buy this auto stock?

The shares of this automotive giant are trading at a 20 percent discount to fair value, and MC Pro recommends investors accumulate the stock for the long term. The outlook is positive, driven by a pent-up demand preference for premiumisation, sharp momentum in exports, significant growth in the CV segment, and an improvement in fleet utilisation. Watch the video to know which stock this is and if you should invest.

Stock Market Live: Colourful Q1 For Asian Paints; Time To Invest? | Markets With Santo & CJ

Asian Paints surprises market with better-than-expected earnings and CJ believes that the stock could now garner interest from investors while Santo still remains sceptical of the valuations of the scrip. Watch the duo spar over whether buying Asian Paints is still value for your money plus their thoughts on Symphony, VRL Logistics and Nykaa.

Ideas For Profit | Syngene: High valuation likely to sustain; Use market correction to buy the stock

Syngene International not only reported a steady set of numbers but also guided for a healthy underlying growth outlook. While it continues to be in the investment phase, risks to watch are execution in the field of biologics and pending regulatory approvals. MC Pro suggests using market corrections to accumulate the stock for the long term. Here's why!